Accelerator mass spect. carcinogen & Anti-Cancer Markers

加速器质谱。

• 批准号: 6403129
• 负责人: BARBARA J HUGHEY
• 金额: $ 20.4万
• 依托单位: NEWTON SCIENTIFIC, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-08-08 至 2003-08-07
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6403129
• 关键词: antineoplastics; biomarker; biomedical equipment development; carbon; carcinogens; high energy particle; mass spectrometry; radionuclides; radiotracer

DESCRIPTION: (provided by applicant) The goal of this program is to develop accelerator mass spectrometry (AMS) as an analytical tool for cancer research, specifically for tracing the interactions of carcinogens and cancer chemotherapeutic drugs with their biomolecular targets. AMS is a highly selective means for detecting and quantifying 14C in labeled biological samples, achieving a measurement sensitivity up to seven orders of magnitude greater than decay counting. Using AMS, 14C tracer studies may be conducted with less administered isotope and with smaller samples containing lower concentrations of isotope than previously possible. Newton Scientific, Inc. and collaborators at the Massachusetts Institute of Technology have developed a compact, low-energy AMS system designed specifically for analysis of biomedical samples. This instrument incorporates a unique continuous-flow interface that allows direct introduction of volatile organic compounds as well as gaseous CO2. The AMS instrument has been interfaced to a standard gas chromatograph, and the development of a liquid chromatograph interface is ongoing. Samples can also be introduced into the AMS as CO2 obtained from off-line oxidation of tissue samples. Phase I of this program is dedicated to bringing the recently constructed AMS instrument to the operational level required for use in tracer studies of carcinogens and chemotherapeutic agents and to using the instrument in proof-of-principle experiments with model compounds. In Phase II, we expect to undertake pilot studies in an ongoing anti-cancer drug development effort at MIT. PROPOSED COMMERCIAL APPLICATION: The biomedical 14C-AMS system used in this program will have widespread commercial applications in the molecular analysis of cancer. With this instrument, it will be possible to conduct studies of carcinogens, mutagens, toxins, and cancer therapeutics using many orders-of-magnitude less tracer activity than is possible today. A potentially important application of AMS is in the area of new durg research. The cost, size and operating requirements of the complete biomedical AMS system will be compatible with installation at major biomedical research centers.

描述：（由申请人提供） 该计划的目标是开发加速器质谱法 (AMS) 癌症研究的分析工具，特别是用于追踪 致癌物和癌症化疗药物的相互作用 生物分子靶标。 AMS 是一种高度选择性的方法，用于检测和 对标记的生物样品中的 14C 进行定量，实现测量 灵敏度比衰变计数高出七个数量级。 使用 AMS，可以使用较少的同位素进行 14C 示踪剂研究 并且样品较小，同位素浓度较低 以前可能。 牛顿科学公司及其合作者 麻省理工学院开发了一种紧凑、低能耗的 AMS 专为分析生物医学样品而设计的系统。这 仪器采用独特的连续流接口，允许直接 引入挥发性有机化合物以及气态CO2。 医疗辅助系统 仪器已与标准气相色谱仪连接，并且 液相色谱仪接口的开发正在进行中。 样品还可以 作为从组织离线氧化获得的 CO2 引入 AMS 样品。 该计划的第一阶段致力于将最近建造的 AMS 仪器达到示踪剂研究所需的操作水平 致癌物和化疗药物以及使用该仪器 使用模型化合物进行原理验证实验。在第二阶段，我们预计 在正在进行的抗癌药物开发工作中进行试点研究 麻省理工学院。 拟议的商业应用： 本项目使用的生物医学14C-AMS系统将具有广泛的商业价值 在癌症分子分析中的应用 有了这个仪器，就可以 使用以下方法进行致癌物、诱变剂、毒素和癌症治疗的研究 示踪剂活动比现在少了许多数量级。 一个潜在的 AMS的重要应用是在新药研究领域。 成本、尺寸和 完整的生物医学 AMS 系统的操作要求将兼容 安装在主要生物医学研究中心。